Accelerate to discover
Related topics
Low-dose imaging in a new preclinical total-body PET/CT scanner
Jun 12, 2019
Ionizing radiation constitutes a health risk to imaging scientists and study animals. Both PET and CT produce ionizing...
Fluxion Biosciences and National Cancer Institute cooperate to validate IsoFlux for sequencing
Jun 12, 2019
Fluxion with IsoFlux has partnered with the Cleveland Clinic. They are aiming to improve sensitivity by timing the...
New insight into Cas9 off-target activity
Jun 7, 2019
Scientists at the MRC London Institute of Medical Sciences and AstraZeneca studied how CRISPR-Cas9 differentiates...
Join the AVANCE Track & Keep your MRI on Track
Jun 4, 2019
Your research depends on the scientific advances that you make with your MRI instrument. Take your instrument and your...
A novel method for isolating high-quality UHMW DNA from animal and human tissues
May 31, 2019
New isolation protocol for isolating high-quality UHMW DNA from 10 mg of freshly frozen or liquid-preserved animal and...
May 27, 2019
The preclinical MRI software ParaVision 7 delivers unsurpassed image quality and enhanced productivity for both routine...
HLS-CATCH: Cas-9 assisted gene purification
May 24, 2019
The CATCH process provides researchers with the most direct access to genes for study. Target regions are defined with...
Introducing the first EV isolation column capable of running 100 mL samples.
May 21, 2019
As the EV field continues to grow and advance, so has the need for scalability in EV isolation. Izon is addressing this...
May 18, 2016
With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.
Get more info
Brand profile
IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.
More info at:
www.intellicyt.com/
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
